- ISIN
- US6024961012
- CUSIP
- 602496101
- Sector
- Healthcare
- Industry
- Medical Devices
- IPO Date
- Aug 22, 2007
Highlights
- Market Cap
- $544.80M
- Enterprise Value
- $388.02M
- EPS (TTM)
- $0.21
- PE Ratio
- 17.85
- PEG Ratio
- 0.00
- Total Revenue (TTM)
- $389.42M
- Gross Profit (TTM)
- $315.59M
- EBITDA (TTM)
- $53.81M
- Year Range
- $3.03 - $7.99
- Target Price
- $10.00
- ROA (TTM)
- 9.94%
- ROE (TTM)
- 12.64%
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
MDXG Performance Chart
MiMedx Group, Inc. (MDXG) is down 45.8% since the beginning of the year. At $4 per share, MDXG is trading 54.1% below its 52-week high of $8. Investors who bought $1,000 worth of MDXG shares 5 years ago would now be looking at an investment worth $332.
Loading charts...
Returns By Period
MiMedx Group, Inc. (MDXG) has returned -45.79% so far this year and -36.83% over the past 12 months. Over the last ten years, MDXG has returned -6.98% per year, falling short of the S&P 500 Index benchmark, which averaged 13.88% annually.
MiMedx Group, Inc.
- 1D
- 0.00%
- 1M
- 1.38%
- YTD
- -45.79%
- 6M
- -47.87%
- 1Y
- -36.83%
- 3Y*
- -17.14%
- 5Y*
- -19.80%
- 10Y*
- -6.98%
Benchmark (S&P 500 Index)
- 1D
- -0.37%
- 1M
- -0.01%
- YTD
- 9.16%
- 6M
- 8.64%
- 1Y
- 25.22%
- 3Y*
- 19.78%
- 5Y*
- 11.99%
- 10Y*
- 13.88%
MDXG Monthly Returns History
Based on dividend-adjusted daily data since Aug 22, 2007, MDXG's average daily return is +0.33%, while the average monthly return is +9.72%. At this rate, an investment would double in approximately 0.6 years.
Historically, 48% of months were positive and 52% were negative. The best month was Feb 2008 with a return of +1,710.0%, while the worst month was Feb 2009 at -62.2%. The longest winning streak lasted 7 consecutive months, and the longest losing streak was 6 months.
On a daily basis, MDXG closed higher 44% of trading days. The best single day was Feb 6, 2008 with a return of +900.0%, while the worst single day was Sep 13, 2021 at -59.6%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -24.52% | -4.31% | -19.22% | -14.94% | 9.52% | -0.27% | -45.79% | ||||||
| 2025 | -9.56% | -3.39% | -9.58% | -9.47% | -6.54% | -4.98% | 17.68% | -1.25% | -1.69% | 9.60% | -10.07% | -1.60% | -29.63% |
| 2024 | -11.74% | 5.43% | -5.64% | -20.00% | 16.07% | -3.08% | 7.50% | -8.19% | -13.60% | 15.91% | 35.04% | 4.00% | 9.69% |
| 2023 | 39.21% | 24.29% | -29.11% | 12.32% | 53.00% | 12.80% | 22.09% | -8.05% | -1.75% | -10.01% | 18.45% | 12.87% | 215.47% |
| 2022 | -17.88% | 1.81% | -6.73% | -16.14% | -1.01% | -11.25% | -1.44% | 3.22% | -18.70% | 3.14% | 9.80% | -14.46% | -53.97% |
| 2021 | 8.15% | 0.92% | 3.94% | -5.83% | 10.21% | 17.03% | -2.00% | 20.39% | -58.94% | 13.04% | 2.34% | -13.84% | -33.48% |
Benchmark Metrics
MiMedx Group, Inc. has an annualized alpha of 115.01%, beta of 0.57, and R2 of 0.00 versus S&P 500 Index. Calculated based on daily prices since August 22, 2007.
- This stock captured 120.26% of S&P 500 Index gains but only 98.88% of its losses - a favorable profile for investors.
- Beta of 0.57 may look defensive, but with R2 of 0.00 this stock is largely uncorrelated with S&P 500 Index - low beta reflects independence, not downside protection. See the Volatility section for a true picture of this stock's risk.
- R2 of 0.00 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- 115.01%
- Beta
- 0.57
- R²
- 0.00
- Upside Capture
- 120.26%
- Downside Capture
- 98.88%
Return for Risk
Risk / Return Rank
MDXG ranks 13 for risk / return — in the bottom 13% of stocks on our site. This means you're taking on significantly more risk than the returns justify. Consider whether the potential upside is worth the volatility, or explore alternatives with better risk / return profiles.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for MiMedx Group, Inc. (MDXG) and compare them to S&P 500 Index.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| MDXG | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -2.89 | ||
| Sortino ratioReturn per unit of downside risk | -3.93 | ||
| Omega ratioGain probability vs. loss probability | 0.86 | 1.37 | -0.51 |
| Calmar ratioReturn relative to maximum drawdown | -0.60 | 2.78 | -3.39 |
| Martin ratioReturn relative to average drawdown | -1.15 | 12.44 | -13.59 |
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the MiMedx Group, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the MiMedx Group, Inc. was 93.83%, occurring on Mar 24, 2009. Recovery took 1031 trading sessions.
The current MiMedx Group, Inc. drawdown is 79.57%.
Related event | Drawdown | Fall | Recovery | Underwater |
|---|---|---|---|---|
Financial crisis2007–2009 | -93.83%Mar 2009 | 11mo 27d | 4y 1mo | 5y 29dApr 2008 - Apr 2013 |
Rate-hike selloffLate 2018 | -93.60%Dec 2018 | 10mo 11d | — | 8y 4moJan 2018 - now |
2016 bear market2016 | -48.65%May 2016 | 9mo 26d | 11mo 27d | 1y 9moJul 2015 - May 2017 |
2013 bear market2013 | -47.65%Sep 2013 | 2mo 26d | 2mo 23d | 5mo 19dJun 2013 - Dec 2013 |
2014 bear market2014 | -41.76%May 2014 | 4mo 5d | 5mo 11d | 9mo 16dJan 2014 - Oct 2014 |
Drawdown Indicators
| MDXG | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -93.83% | -56.78% | -37.05% |
Max Drawdown (1Y)Largest decline over 1 year | -61.24% | -9.10% | -52.14% |
Max Drawdown (3Y)Largest decline over 3 years | -68.36% | -18.90% | -49.46% |
Max Drawdown (5Y)Largest decline over 5 years | -83.39% | -25.43% | -57.96% |
Max Drawdown (10Y)Largest decline over 10 years | -93.60% | -33.92% | -59.68% |
Current DrawdownCurrent decline from peak | -79.57% | -1.80% | -77.77% |
Average DrawdownAverage peak-to-trough decline | -53.56% | -10.71% | -42.85% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 32.14% | 2.03% | +30.11% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of MiMedx Group, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how MiMedx Group, Inc. is priced in the market compared to other companies in the Medical Devices industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PE Ratio
The chart displays the Price-to-Earnings (P/E) ratio for MDXG, comparing it with other companies in the Medical Devices industry. Currently, MDXG has a P/E ratio of 17.9. This P/E ratio is in line with the industry average, suggesting the stock may be fairly valued relative to its earnings.
PEG Ratio
The chart shows the Price/Earnings to Growth (PEG) ratio for MDXG compared to other companies in the Medical Devices industry. MDXG currently has a PEG ratio of 0.0. This PEG ratio is low compared to industry peers, which could indicate the stock is undervalued relative to its expected growth.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for MDXG relative to other companies in the Medical Devices industry. Currently, MDXG has a P/S ratio of 1.4. This P/S ratio falls within the average range for the industry, suggesting the stock is fairly valued based on its revenue.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for MDXG in comparison with other companies in the Medical Devices industry. Currently, MDXG has a P/B value of 2.2. This P/B ratio is in line with the industry average, suggesting the stock is valued fairly in relation to its book value.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with MDXG
Add MiMedx Group, Inc. to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with MDXG